Alzamend Neuro (ALZN) vs Scienture (SCNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alzamend Neuro is the larger company by market cap ($6.5 million vs $6.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | SCNX |
|---|---|---|
| Share price | $1.34 | $3.76 |
| Market cap | $6.47M | $6.18M |
| 1-day change | 0.00% | -2.59% |
| EPS (TTM) | $-2.30 | $-52.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $65.00 |
| 52-week low | $0.84 | $3.23 |
| Distance from 52-week high | -50.00% | -94.22% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1840.30% | +897.34% |
| Average volume | 87.36K | 183.47K |
| Shares outstanding | 4.83M | 1.64M |
| Employees | 4 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Scienture
SCNX stock →Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ALZN vs SCNX FAQ
Which is bigger, Alzamend Neuro or Scienture?
Alzamend Neuro (ALZN) is larger, with a market capitalization of $6.47M compared with $6.18M for Scienture (SCNX).
Are Alzamend Neuro and Scienture in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.